X
BHVN

Xponance’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Xponance’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-3,542
Closed -$535K – 1261
2022
Q3 		$535K Buy
3,542
+166
+5% +$24.6K 0.01% 820
2022
Q2 		$492K Buy
3,376
+736
+28% +$94K 0.01% 864
2022
Q1 		$313K Buy
2,640
+21
+0.8% +$2.62K 0.01% 1019
2021
Q4 		$361K Buy
2,619
+1
+0% +$127 0.01% 1011
2021
Q3 		$364K Sell
2,618
-341
-12% -$42.6K 0.01% 1000
2021
Q2 		$287K Buy
+2,959
New +$240K 0.01% 1082

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Xponance's BHVN Position: Q4 2022 in Review

Xponance sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 3,542 shares — an estimated $535K sold.

Xponance first reported a position in BHVN in Q2 2021 and held it in 6 quarters. The position peaked at $535K in Q3 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Xponance reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Xponance sold 3,542 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $535K.
  • Xponance first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q2 2021 and held it in 6 quarters.
  • Xponance's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $535K in Q3 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Xponance's 13F filing for Q4 2022, filed 24 Jan 2023.